Anticancer Agents from Natural Products | Agenda Bookshop Skip to content
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=David G. I. Kingston
B01=David J. Newman
B01=Gordon M. Cragg
Category1=Non-Fiction
Category=MMG
Category=PN
Category=PSA
COP=United Kingdom
Delivery_Pre-order
Language_English
PA=Not yet available
Price_€50 to €100
PS=Forthcoming
softlaunch

Anticancer Agents from Natural Products

English

The approach to drug discovery from natural sources has yielded many important new pharmaceuticals inaccessible by other routes. In many cases the isolated natural product may not be an effective drug for any of several reasons, but it nevertheless may become a drug through chemical modification or have a novel pharmacophore for future drug design. In summarizing the status of natural products as cancer chemotherapeutics, Anticancer Agents from Natural Products, Second Edition covers the:

  • History of each covered druga discussion of its mechanism on action, medicinal chemistry, synthesis, and clinical applications
  • Potential for novel drug discovery through the use of genome mining as well as future developments in anticancer drug discovery
  • Important biosynthetic approaches to unnatural natural products

Anticancer Agents from Natural Products, Second Edition discusses how complex target-oriented synthesisenabled by historic advances in methodologyhas enormously expanded the scope of the possible. This book covers the current clinically used anticancer agents that are either natural products or are clearly derived from natural product leads. It also reviews drug candidates currently in clinical development since many of these will be clinically used drugs in the future.

Examples include the drugs etoposide and teniposide derived from the lead compound podophyllotoxin; numerous analogs derived from taxol; topotecan, derived from camptothecin; and the synthetic clinical candidates, E7389 and HTI-286, developed from the marine leads, halichondrin B and hemiasterlin.

See more
Current price €54.14
Original price €56.99
Save 5%
Age Group_Uncategorizedautomatic-updateB01=David G. I. KingstonB01=David J. NewmanB01=Gordon M. CraggCategory1=Non-FictionCategory=MMGCategory=PNCategory=PSACOP=United KingdomDelivery_Pre-orderLanguage_EnglishPA=Not yet availablePrice_€50 to €100PS=Forthcomingsoftlaunch

Will deliver when available. Publication date 14 Oct 2024

Product Details
  • Weight: 1450g
  • Dimensions: 178 x 254mm
  • Publication Date: 14 Oct 2024
  • Publisher: Taylor & Francis Ltd
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9781032917535

About

Gordon M. Cragg obtained his undergraduate training in chemistry at Rhodes University South Africa and his D. Phil. (organic chemistry) from Oxford University. After two years of postdoctoral research at the University of California Los Angeles he returned to South Africa to join the Council for Scientific and Industrial Research. In 1966 he joined the Chemistry Department at the University of South Africa and transferred to the University of Cape Town in 1972. In 1979 he returned to the US to join the Cancer Research Institute at Arizona State University working with Professor G. R. Pettit. In 1985 he moved to the National Cancer Institute (NCI) National Institutes of Health (NIH) in Bethesda Maryland and was appointed Chief of the NCI Natural Products Branch in 1989. He retired in December 2004 and is currently serving as an NIH Special Volunteer. His major interests lie in the discovery of novel natural product agents for the treatment of cancer and AIDS with an emphasis on multidisciplinary and international collaboration. He has given over 100 invited talks at conferences in many countries worldwide and has been awarded NIH Merit Awards for his contributions to the development of the anticancer drug Taxol (1991) leadership in establishing international collaborative research in biodiversity and natural products drug discovery (2004) and contributions to developing and teaching NIH technology transfer courses (2004). He was President of the American Society of Pharmacognosy in 1998-1999 was elected to Honorary Membership of the Society in 2003 and was named a Fellow of the Society in 2008. In November 2006 he was awarded the William L. Brown Award for Plant Genetic Resources by Missouri Botanical Garden which also named a recently discovered Madagascar plant in his honor Ludia craggiana and in April 2010 he was awarded an Honorary Doctorate of Science by his South African alma mater Rhodes University.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept